

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	
				Confirmation Number	6094
				Filing Date	
				First Named Inventor	Tadashi TANABE
				Art Unit	1645
				Examiner Name	Patrica A. Duffy
				Attorney Docket Number	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Pereira B. Et al., "Bovine Prostacyclin Synthase: Purification and Isolation of Partial CDNA" Biochemical and Biophysical Research Communications, Academic Press Inc. Orlando, FL US, vol. 197, No. 3, December 30, 1993; pages 1041-1048 XP000570379 ISSN: 0006-291X Abstract page 1047; Figure 4	
		Satoh K. et al. "Role of prostaglandins in pregnancy-induced hypertension: AM J. Kidney, vol. 17, No. 2, February 1991 (1991-02), pgs. 133-138, XP001062950 page 133.	
		Gryglewski RJ et al. "Prostacyclin and Vascular disease" Philos Trans R Soc Lond B Biol. Sci, vol. 294, No. 1072, August 18, 1981 (pages 383-388, XP001062949 page 383.	
		Supplementary European Search Report	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Form PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent & Trademark Office		Atty. Docket No. 	Serial No. 		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Cont. Appln. Under 1.53(b) of U.S. Appln. No. 			
Filing Date:				Group: 1645			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
		Document	Date	Country	Class	Sub-class	Translation Yes/No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Ngo et al (1994) Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox. In: The Protein Folding Problem and Tertiary Structure Prediction, Eds. Merz et al., Birkhauser, Boston, MA pages 491-495.					
		Bimodal Distribution of the Prostaglandin I ₂ Synthase Antigen in Smooth Muscle Cells, W. Smith et al, <u>The Journal of Biological Chemistry</u> , pp. 5922-5926, dtd. 1983					
		Purification, Quantitation, and Localization of PGI ₂ Synthase Using Monoclonal Antibodies, W. Smith et al, pp. 87-92, dtd. 1983					
		Eighth Gaddum Memorial Lecture University of London Institute of Education December 1980, Biological Importance of Prostacyclin, S. Moncada, pp. 1-31, dtd. 1982					
		Agonist-Specific Desensitization of PGI ₂ -Stimulated Cyclic AMP Accumulation by PGE ₁ In Human Foreskin Fibroblasts, R. Gorman et al, pp. 3-17, dtd. 1980					
		Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications, Proceedings of the 4 th International Conference on Cytochrome P-450 held in Kuopio, Finland, May 31-June 3, 1992, E. Hietanen et al, eds., pp. 103-106, dtd. 1982					
		Purification of Prostacyclin Synthase from Bovine Aorta By Immunoaffinity Chromatography, D. DeWitt et al, <u>The Journal of Biological Chemistry</u> , pp. 3285-3293, dtd. 3/83					
		Molecular Characterization of the Prostacyclin Synthase, <u>Advances in Prostaglandin, Thromboxane, and Leukotriene Research</u> , M. Inoue, pp. 29-33, dtd. 1987					
		Bovine Prostacyclin Synthase: Purification and Isolation of Partial cDNA, <u>Biochemical and Biophysical Communications</u> , B. Pereira et al, pp. 1041-1048, dtd. 1993					
		Structure-function relationships of membrane-bound heme-enzyme, cytochrome P450, Institute for Chemical Reaction Science, Tohoku University, T. Shimizu, pp. 10-15, dtd. 1992					
		Preparation and Assay of Prostacyclin Synthase, <u>Methods in Enzymology</u> , J. Salmon et al, pp. 91-99, dtd. 1982					
		Molecular Cloning of Prostacyclin Synthase From Bovine Endothelial Cells, <u>Eicosanoids & Other BioActive Lipids in Cancer, Inflammation & Radiation Injury</u> , T. Tanabe et al, pp. 137, dtd. 1993					
		Tanabe et al in "Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 23, 1995, pp. 133-135					
		Govindarajan, et al, <u>The Pathology</u> , 7(4):654-659, 1987					
		Keirse et al, <u>Placenta</u> , 7:37-42, 1986					
		Siegle et al, <u>FEBS Letters</u> , 347:221-225 (1994)					
		Dewitt et al, <u>Methods in Enzymology</u> , vol. 86:240-246, 1982					
		Moonen et al, <u>Europ. J. Obstet. Gynec. reprod. Biol.</u> 19:151-158, 1985					
		Harlow et al, <u>Antibodies a Laboratory Manual</u> , Cold Spring Harbor Laboratories, 1989, Chap. 8, pp. 283-318					
EXAMINER:				DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.							